Vera Therapeutics (Nasdaq: VERA) announced inducement awards granted May 4, 2026 to ten new employees under its 2024 Inducement Plan. The Compensation Committee granted non-qualified stock options for 40,250 shares and RSUs underlying 20,125 shares.
Each option has an exercise price of $35.51 (closing price May 4, 2026). Options vest over four years (25% after one year, then monthly over 36 months). RSUs vest 25% annually beginning May 20, 2026. Awards are subject to the Inducement Plan and individual award agreements.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – VERA
+1.16%
+1.16%Session close to close
In the May 11 session, VERA gained 1.16%, reflecting a mild positive market reaction.
This announcement details new inducement equity awards totaling options on 40,250 shares and 20,125 ...
Analysis
This announcement details new inducement equity awards totaling options on 40,250 shares and 20,125 RSUs for ten employees, with a $35.51 exercise price and four-year vesting schedules. It follows several similar grants under the 2024 Inducement Plan. Investors may contextualize this alongside recent SEC filings highlighting operating losses, cash resources, and pending regulatory milestones when evaluating the overall impact of continued share-based compensation.
Key Figures
Stock options granted:40,250 sharesRSUs granted:20,125 sharesNew employees:10 employees+5 more
8 metrics
Stock options granted40,250 sharesNon-qualified options under 2024 Inducement Plan to new employees
RSUs granted20,125 sharesRestricted stock units under 2024 Inducement Plan to new employees
New employees10 employeesRecipients of inducement equity awards on May 4, 2026
Option exercise price$35.51 per shareEqual to Vera’s May 4, 2026 closing trading price
Option vesting period4 years25% after one year, remainder monthly over 36 months
Initial vesting cliff25%First anniversary of vesting commencement date for options
Monthly vesting duration36 monthsRemaining option shares after initial 25% cliff
RSU vesting schedule25% annually over 4 yearsOn each anniversary of May 20, 2026, subject to service
Inducement awards to six new employees under 2024 Inducement Plan.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent inducement grant announcements were followed by 24-hour moves of -2.95%, -1.96%, and -0.26%, suggesting modest negative or muted reactions around similar equity award news.
Recent Company History
Over the past two months, Vera issued multiple inducement equity awards under its 2024 Inducement Plan and made a key legal hire. Inducement grant press releases on Mar 3, Mar 23, and Apr 8, 2026 were followed by small negative moves, while the appointment of a Chief Legal Officer on Mar 25, 2026 saw a modest gain. A recent conference participation announcement on May 4, 2026 coincided with a slight positive reaction.
"granted inducement awards... in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
non-qualified stock optionsfinancial
"granted inducement awards consisting of non-qualified stock options to purchase 40,250 shares"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
restricted stock unitsfinancial
"and restricted stock units (RSUs) underlying 20,125 shares of Class A common stock"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
rsusfinancial
"and restricted stock units (RSUs) underlying 20,125 shares of Class A common stock"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
class a common stockfinancial
"to purchase 40,250 shares of Class A common stock and restricted stock units"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
BRISBANE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on May 4, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 40,250 shares of Class A common stock and restricted stock units (RSUs) underlying 20,125 shares of Class A common stock to ten (10) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option granted on May 4, 2026 has an exercise price per share equal to $35.51, Vera Therapeutics’ closing trading price on May 4, 2026. Each stock option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. Each of the RSU awards will vest over four years, with 25% of the underlying shares vesting on each anniversary of May 20, 2026, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
AboutVera Therapeutics Vera Therapeutics is a biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics’ mission is to advance treatments that target the source of disease in order to change the standard of care for patients. Vera Therapeutics’ lead product candidate is atacicept, a fusion protein self-administered at home as a subcutaneous once weekly injection that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including immunoglobulin A nephropathy (IgAN) and lupus nephritis. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful. In addition, Vera Therapeutics holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell-mediated diseases. Vera Therapeutics is also evaluating development of MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109 and MAU868. For more information, please visit www.veratx.com.
What inducement awards did Vera Therapeutics (VERA) grant on May 4, 2026?
Vera granted non-qualified stock options for 40,250 shares and RSUs for 20,125 shares to ten new employees. According to the company, awards were approved under its 2024 Inducement Plan pursuant to Nasdaq Rule 5635(c)(4).
What is the exercise price and how was it set for VERA stock options granted May 4, 2026?
Each option’s exercise price is $35.51, equal to the closing trading price on May 4, 2026. According to the company, the exercise price matches that closing market price on the grant date.
What vesting schedule applies to the VERA stock options and RSUs granted to new hires?
Options vest over four years: 25% after one year, then monthly over 36 months; RSUs vest 25% on each anniversary starting May 20, 2026. According to the company, vesting is subject to continued service through each vesting date.
How many employees received inducement awards from Vera Therapeutics (VERA) in this grant?
Ten new employees received inducement awards in this grant. According to the company, the Compensation Committee approved awards as material inducements to those hires under Nasdaq Listing Rule 5635(c)(4).
Are the May 4, 2026 VERA awards subject to additional terms or agreements?
Yes. Awards are subject to the terms of the 2024 Inducement Plan and individual award agreements. According to the company, each grant will follow the plan rules and the applicable award agreement provisions.
